LONDON – A potentially breakthrough cancer killing treatment being developed by LIfT BioSciences is attracting major new investment.
Investors including Johnston Milner, a renowned biotech ‘super-angel’, Kizoo Technology Ventures and Downing Ventures are helping LIfT in its quest to pioneer the first curative and affordable cell therapy for all solid tumours.
“LIfT has developed and patented the most promising cancer therapy I have come across to date,” said Jonathan Milner.
Alex Blyth, CEO of LIfT BioSciences believes N-LIfT, the company’s first product, has the potential to generate a ‘paradigm-shifting change in how we treat cancer’.
“Rapidly dividing cancer cells are able to adapt whereas targeted therapies are not,” he explains. “This is a major flaw with current treatment options for patients, as their cancers are often only temporarily slowed before mutating and returning aggressively. Until now the only other approach has been broad chemotherapies that are essentially only slightly more toxic to cancer cells than healthy cells. Whereas N-LIfT is a smart living therapy that selectively destroys any cancer cell we throw at it, regardless of type, mutational status or whether they are hot or cold tumours. N-LIfT also has the potential to improve the performance of other therapies that struggle with solid tumours and cold (non-inflamed) tumour environments.”
LIfT BioSciences will now invest in further developing its manufacturing technology to produce N-LIfT. The company said it is looking to demonstrate in-vivo superiority over standard of care in Pancreatic Ductal Adenocarcinoma (PDAC), Non-Small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC). Venture capitalists and private family wealth funds are invited to join the investment syndicate, to help fund early clinical trials.
